Histiocytic disorders (LCH, ECD, Rosai-Dorfman, HLH)
The family of clonal and inflammatory histiocytic proliferations transformed by the Badalian-Very 2010 Blood discovery of BRAF-V600E in Langerhans Cell Histiocytosis — the landmark that moved this field from 'mysterious' rare disease into precision medicine. Langerhans Cell Histiocytosis (LCH) — clonal proliferation of CD1a+/CD207+ Langerhans cells with BRAF-V600E in ~55% of cases; spectrum from single-system (bone, skin) to multi-system disease with risk-organ involvement (liver, spleen, hematopoietic); pediatric and adult disease; LCH-associated neurodegeneration is a late complication. Erdheim-Chester Disease (ECD) — rare adult-onset non-Langerhans histiocytosis; foamy CD68+/CD1a-/S100- histiocytes with MAPK pathway mutations (BRAF-V600E ~50%, MAP2K1, NRAS, KRAS); multi-system with long-bone osteosclerosis, 'hairy kidney' perinephric fibrosis, cardiac mass, retroperitoneal fibrosis, CNS involvement. Rosai-Dorfman Disease (RDD) — sinus histiocytosis with massive lymphadenopathy; S100+/CD68+/CD1a- histiocytes with emperipolesis; self-limited in many, aggressive in a subset; MAPK and KIF5B mutations. Hemophagocytic Lymphohistiocytosis (HLH) — life-threatening cytokine storm; primary (familial, FHL) PRF1 / UNC13D / STX11 / STXBP2 mutations with infantile onset, or secondary (EBV-triggered, autoimmune-associated, lymphoma-associated); cardinal criteria fever + cytopenias + hepatosplenomegaly + hyperferritinemia + hypertriglyceridemia + hypofibrinogenemia. Standard-of-care frameworks: LCH-III vinblastine + prednisone backbone, BRAF/MEK inhibition (VEMURAFENIB / Zelboraf, Roche/Genentech, and DABRAFENIB + TRAMETINIB / Tafinlar + Mekinist, Novartis) for BRAF-V600E disease, cladribine, allogeneic HSCT for refractory; ECD VEMURAFENIB (Zelboraf) FDA-APPROVED NOVEMBER 2017 — landmark precision-medicine approval — plus COBIMETINIB (Cotellic) combinations; RDD cobimetinib / MEK inhibition for refractory, sirolimus, cladribine, methotrexate; HLH-94 and HLH-2004 international protocols (etoposide + dexamethasone + cyclosporine), EMAPALUMAB (Gamifant, Sobi) anti-IFN-gamma mAb FDA-APPROVED NOVEMBER 2018 for primary HLH, RUXOLITINIB (Jakafi, Incyte) JAK1/2 for refractory, allogeneic HSCT curative for FHL. Histiocytosis Association (histio.org) + Erdheim-Chester Disease Global Alliance + Rosai-Dorfman Disease Foundation + Histiocyte Society international research consortium + HLH-94/2004 trial cohorts. Ninety-second deliberate non-elevation of community peptides.
What changes during this transition
Histiocytic disorders are a family of clonal and inflammatory proliferations of histiocytes — tissue macrophages and dendritic cells — that was transformed editorially and clinically by the Badalian-Very et al. 2010 Blood discovery of BRAF-V600E mutation in approximately 55% of Langerhans Cell Histiocytosis cases. That single discovery moved the entire histiocytic-disorder family from a 'mysterious' rare-disease grouping into a precision-medicine landscape where BRAF/MEK pathway inhibition has produced multiple FDA approvals, including the landmark November 2017 vemurafenib (Zelboraf, Roche/Genentech) FDA approval for BRAF-V600E Erdheim-Chester Disease — the first FDA-approved targeted therapy in any histiocytic disorder. LCH is the most common entity, frequently pediatric-onset, characterized by clonal proliferation of CD1a+ and CD207+ Langerhans cells with a clinical spectrum from single-system disease (isolated bone, isolated skin) through multi-system disease with risk-organ involvement (liver, spleen, hematopoietic). Hypothalamic-pituitary infiltration in multi-system LCH is editorially load-bearing — central diabetes insipidus is the most common LCH-driven pituitary manifestation, and anterior pituitary deficiencies including growth hormone deficiency follow. LCH-III vinblastine + prednisone backbone with BRAF/MEK inhibition (vemurafenib, dabrafenib + trametinib) for BRAF-V600E disease, cladribine, allogeneic HSCT refractory. ECD is rare adult-onset non-Langerhans histiocytosis with foamy CD68+ / CD1a- / S100- histiocytes and MAPK pathway mutations (BRAF-V600E ~50% plus MAP2K1, NRAS, KRAS), multi-system phenotype including pathognomonic long-bone osteosclerosis, 'hairy kidney' perinephric fibrosis, cardiac involvement, retroperitoneal fibrosis, CNS disease. November 2017 vemurafenib (Zelboraf) FDA approval for BRAF-V600E ECD is the landmark editorial event — first FDA approval anywhere in histiocytosis. Cobimetinib (Cotellic) + vemurafenib combinations and dabrafenib + trametinib alternatives extend the BRAF/MEK era. RDD is sinus histiocytosis with massive lymphadenopathy characterized by S100+ / CD68+ / CD1a- histiocytes with emperipolesis. HLH is the life-threatening cytokine-storm entity — primary HLH (FHL) driven by biallelic PRF1, UNC13D, STX11, STXBP2 with infantile presentation; secondary HLH triggered by infection (EBV particularly), autoimmune disease (macrophage activation syndrome in juvenile idiopathic arthritis and adult Still's disease), or malignancy. HLH-94 and HLH-2004 international protocols form the backbone, with emapalumab (Gamifant, Sobi) anti-IFN-gamma mAb FDA-approved November 2018 for primary HLH as the second landmark precision-medicine FDA approval, ruxolitinib (Jakafi, Incyte) for refractory HLH, allogeneic HSCT curative for FHL. International research infrastructure is multi-jurisdictional: Histiocytosis Association (histio.org), Erdheim-Chester Disease Global Alliance, Rosai-Dorfman Disease Foundation, Histiocyte Society. Pediatric editorial sensitivity is load-bearing — LCH frequently pediatric-onset, FHL infantile-onset, families navigating life-threatening cytokine storm in infants are a known vector for community peptide market exploitation. No peptide in the Juno library has a discovery-card-defensible histiocytic-disorder case. BPC-157 collides with clonal-histiocytic-proliferation reality in LCH, ECD, and aggressive RDD. NMN reaches the population through general-aging channel in adult ECD demographic on indefinite vemurafenib + cobimetinib. The GH-axis trio overlaps with pediatric-LCH growth questions where LCH-driven hypothalamic-pituitary infiltration is documented — tesamorelin Rule 6 non-propagation is sharpest. Semaglutide is the coordination-of-care conversation for chronic-BRAF-inhibitor + chronic-steroid metabolic syndrome. Ninety-second deliberate non-elevation.
Important caveat
Histiocytic disorders are histiocytic-disorder-specialist-managed — pediatric hematology-oncology for pediatric LCH and FHL, adult hematology-oncology + ECD-experienced centers for adult ECD, hematology + rheumatology + infectious disease for HLH, multi-specialist coordination across endocrinology (LCH hypothalamic-pituitary infiltration, central DI, GHD), cardiology (ECD cardiac involvement), neurology (LCH-associated neurodegeneration, ECD CNS), nephrology (ECD 'hairy kidney'), and BMT (allogeneic HSCT). **THE BADALIAN-VERY 2010 BLOOD BRAF-V600E DISCOVERY transformed this field from 'mysterious' rare disease into precision medicine** — BRAF-V600E mutation status is editorially load-bearing because it drives BRAF/MEK-inhibitor eligibility. **STANDARD OF CARE**: LCH — LCH-III vinblastine + prednisone, BRAF/MEK inhibition (VEMURAFENIB / Zelboraf, Roche/Genentech; DABRAFENIB + TRAMETINIB / Tafinlar + Mekinist, Novartis), cladribine, allogeneic HSCT refractory. ECD — **VEMURAFENIB FDA-APPROVED NOVEMBER 2017 for BRAF-V600E ECD as the landmark precision-medicine approval**, COBIMETINIB (Cotellic) combinations, dabrafenib + trametinib alternatives. RDD — cobimetinib / MEK inhibition refractory, sirolimus, cladribine, methotrexate. HLH — **HLH-94 and HLH-2004 international protocols** (etoposide + dexamethasone + cyclosporine), **EMAPALUMAB (Gamifant, Sobi) FDA-APPROVED NOVEMBER 2018** for primary HLH, **RUXOLITINIB (Jakafi, Incyte) JAK1/2** for refractory HLH, allogeneic HSCT curative for FHL. **PEDIATRIC EDITORIAL SENSITIVITY LOAD-BEARING** — LCH frequently pediatric-onset and FHL infantile-onset; community peptide market reaches desperate pediatric rare-disease families. **HYPOTHALAMIC-PITUITARY INFILTRATION in multi-system LCH** drives central DI and anterior pituitary deficiencies including GHD — formal pediatric endocrinology workup with full anterior pituitary axis testing including GH stimulation is the supervised pathway, not community GH-secretagogue peptides. **LCH-ASSOCIATED NEURODEGENERATION** is a recognized late complication requiring long-term MRI brain surveillance. **MULTI-JURISDICTIONAL INFRASTRUCTURE**: Histiocytosis Association (histio.org), Erdheim-Chester Disease Global Alliance, Rosai-Dorfman Disease Foundation, Histiocyte Society, HLH-94/HLH-2004 international trial cohorts. **COMMUNITY PEPTIDES Tier 3**: **BPC-157** — pro-angiogenic VEGF / NO mechanism uncharacterized in clonal histiocytic proliferation; SC bleed-risk in HLH cytopenias; SC injection on chronic BRAF/MEK-inhibitor cytopenia + photosensitivity background. **NMN** — general-aging framing in adult ECD survivors on indefinite vemurafenib + cobimetinib. **GH-AXIS TRIO** — pediatric-LCH growth question with LCH-driven hypothalamic-pituitary infiltration and chronic LCH-III prednisone steroid burden; disease control plus formal endocrine workup is the lever; somatropin under pediatric endocrinology is the supervised pathway. **TESAMORELIN**: **Rule 6 non-propagation SHARPEST** — HIV-LD FDA label does NOT extend to LCH or ECD or RDD or HLH; active-clonal-proliferation reality makes the FDA label active-malignancy contraindication non-trivial. **SEMAGLUTIDE** — coordination-of-care for chronic-BRAF-inhibitor + chronic-steroid metabolic syndrome with BRAF/MEK-inhibitor interaction surveillance (vemurafenib + dabrafenib hepatotoxicity + QTc + photosensitivity + cutaneous SCC + pancreatitis class effect; cobimetinib ophthalmologic; trametinib LV ejection fraction) and post-HSCT infection surveillance. **NO Juno library peptide is surfaced as a histiocytic-disorder discovery card** — 92nd deliberate non-elevation. WADA: BPC-157 (S0) + CJC-1295 + ipamorelin + tesamorelin (S2) prohibited at all times; vemurafenib + dabrafenib + cobimetinib + trametinib + emapalumab + ruxolitinib + cladribine + etoposide + dexamethasone + cyclosporine TUE candidates. **RED FLAGS**: fever in any HLH-spectrum or post-HSCT FHL patient (HLH relapse or post-HSCT infection emergency); new neurologic symptoms in LCH (LCH-associated neurodegeneration progression or CNS LCH); new cardiac symptoms in ECD (ECD cardiac progression with intracardiac mass or pericardial effusion); rising ferritin or falling fibrinogen in HLH (cytokine-storm relapse); new abdominal pain on semaglutide titration in chronic BRAF-inhibitor patient (BRAF/MEK-inhibitor pancreatitis vs GLP-1 pancreatitis disambiguation); new skin lesion on BRAF-inhibitor therapy (cutaneous SCC surveillance); growth-velocity slowdown in pediatric LCH (LCH-driven pituitary infiltration vs steroid suppression disambiguation).
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.